Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) EBT Margin: 2011-2025

Historic EBT Margin for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to 14.84%.

  • Ani Pharmaceuticals' EBT Margin rose 3607.00% to 14.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.11%, marking a year-over-year increase of 746.00%. This contributed to the annual value of -3.62% for FY2024, which is 770.00% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' EBT Margin stood at 14.84%, which was up 197.96% from 4.98% recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' EBT Margin peaked at 18.43% during Q1 2024, and registered a low of -50.64% during Q4 2021.
  • For the 3-year period, Ani Pharmaceuticals' EBT Margin averaged around 3.12%, with its median value being 4.50% (2023).
  • As far as peak fluctuations go, Ani Pharmaceuticals' EBT Margin slumped by 4,651bps in 2021, and later soared by 4,456bps in 2022.
  • Ani Pharmaceuticals' EBT Margin (Quarterly) stood at -50.64% in 2021, then skyrocketed by 4,456bps to -6.08% in 2022, then skyrocketed by 680bps to 0.72% in 2023, then crashed by 794bps to -7.22% in 2024, then skyrocketed by 3,607bps to 14.84% in 2025.
  • Its EBT Margin was 14.84% in Q3 2025, compared to 4.98% in Q2 2025 and 10.14% in Q1 2025.